Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alto Neuroscience (ANRO) Retained Earnings (2023 - 2026)

Alto Neuroscience has reported Retained Earnings over the past 4 years, most recently at -$227.9 million for Q1 2026.

  • Quarterly results put Retained Earnings at -$227.9 million for Q1 2026, down 48.37% from a year ago — trailing twelve months through Mar 2026 was -$227.9 million (down 48.37% YoY), and the annual figure for FY2025 was -$201.6 million, down 199537.62%.
  • Retained Earnings reached -$227.9 million in Q1 2026 per ANRO's latest filing, down from -$201.6 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$79000.0 in Q4 2023 and bottomed at -$227.9 million in Q1 2026.
  • Median Retained Earnings over the past 4 years was -$130.0 million (2024), compared with a mean of -$104.7 million.
  • The largest annual shift saw Retained Earnings fell 27.85% in 2024 before it tumbled 199537.62% in 2025.
  • Over 4 years, Retained Earnings stood at -$79000.0 in 2023, then decreased by 27.85% to -$101000.0 in 2024, then crashed by 199537.62% to -$201.6 million in 2025, then fell by 13.03% to -$227.9 million in 2026.
  • Business Quant data shows Retained Earnings for ANRO at -$227.9 million in Q1 2026, -$201.6 million in Q4 2025, and -$185.5 million in Q3 2025.